Ejaculatory DysfunctionNCT06605469
Ejaculatory and Orgasmic Dysfunction Registry
An observational study of Ejaculatory Dysfunction and Premature Ejaculation, run by Charitable Union for the Research and Education of Peyronie's Disease at 1 site in United States.
Trial summary
The goal of this observational study is to evaluate the safety and efficacy of various therapies used to treat ejaculatory and/or orgasmic dysfunctions in men. The objective is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and/or orgasmic dysfunction. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Ejaculatory Dysfunction, Premature Ejaculation, Delayed Ejaculation
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 30 May 2024to 31 May 2029
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult men (>18) diagnosed with ejaculatory and/or orgasmic dysfunction who were recommended to begin any treatment for the condition For partners, inclusion is being a sexual partner of a man with ejaculatory and/or orgasmic dysfunction who is receiving treatment
Who may be able to join
- Men being treated for either ejaculatory and/or orgasmic dysfunction
- For partners, inclusion is being a sexual partner of a man with ejaculatory and/or orgasmic dysfunction who is receiving treatment
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
The Male Fertility and Peyronie's Clinic
Orem, Utah, 84057
Landon Trost, MD, (888) 655-0015, email@mfp.clinic
Holli Burgon
About this study
Official title: Ejaculatory and Orgasmic Dysfunction Registry (Climax Registry)
The goal of this observational study is to evaluate the safety and efficacy of various therapies used to treat ejaculatory and/or orgasmic dysfunctions in men. The objective is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and/or orgasmic dysfunction.
Participants will submit questionnaires about their diagnosis and treatment efficacy and multiple time intervals.
Read the detailed description
The objective of the current study is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and/or orgasmic dysfunction. To accomplish this registry, CURE PD has partnered with the Sexual Medicine Society of North America (SMSNA) to help inform sexual medicine providers of the existence of the study and to help encourage patients to enroll.
Subjects meeting criteria will be offered study entry by their local provider who will refer them to an email address to indicate their interest. Participants will then be administered questionnaires at baseline and every 3 months x 1 year, followed by every 6 months x 2 years. Patient partners will also be allowed to enroll and will receive questionnaires on the same schedule (baseline, q3 months x 1 year, q6 months x 2 years).
- Conditions
- Ejaculatory Dysfunction, Premature Ejaculation, Delayed Ejaculation, Anorgasmia, Anejaculation, Dysejaculation
- Keywords
- ejaculatory dysfunction, premature ejaculation, delayed ejaculation, anorgasmia, anejaculation, dysejaculation, dysorgasmia
- Medical subject headings
- Ejaculatory Dysfunction, Premature Ejaculation
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Objective
Report subjective efficacy of therapies used to treat ejaculatory dysfunction. Study participants will have the option of indicating if they had used any treatments to treat ejaculatory disorders. If so, they will then be asked to measure its efficacy at improving their symptoms using a 1-10 scale (10 being very effective).
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2024
- Study start30 May 2024
- Primary completion31 May 2029 (estimated)
- Study completion31 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ejaculatory DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Charitable Union for the Research and Education of Peyronie's Disease
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06605469
- Sponsor's protocol ID
- CUREPD200
- Status last verified
- Aug 2026
- First submitted
- 13 Jun 2024
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Deidentified data will be made available to sites which have referred patients to the registry.
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ejaculatory and Orgasmic Dysfunction Registry (Climax Registry)
- ClinicalTrials.gov ID
- NCT06605469
- Acronym / sponsor ID
- CUREPD200
- Conditions
- Ejaculatory Dysfunction, Premature Ejaculation, Delayed Ejaculation, Anorgasmia, Anejaculation, Dysejaculation
- Keywords
- ejaculatory dysfunction, premature ejaculation, delayed ejaculation, anorgasmia, anejaculation, dysejaculation, dysorgasmia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Charitable Union for the Research and Education of Peyronie's DiseaseUniversity, hospital or other
- Study start
- 30 May 2024 (actual)
- Primary completion
- 31 May 2029 (estimated)
- Study completion
- 31 May 2029 (estimated)
- First posted
- 20 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate the safety and efficacy of various therapies used to treat ejaculatory and/or orgasmic dysfunctions in men. The objective is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and/or orgasmic dysfunction.
Participants will submit questionnaires about their diagnosis and treatment efficacy and multiple time intervals.
Detailed description
The objective of the current study is to create a large, national registry designed to capture key outcomes for men being treated for ejaculatory and/or orgasmic dysfunction. To accomplish this registry, CURE PD has partnered with the Sexual Medicine Society of North America (SMSNA) to help inform sexual medicine providers of the existence of the study and to help encourage patients to enroll.
Subjects meeting criteria will be offered study entry by their local provider who will refer them to an email address to indicate their interest. Participants will then be administered questionnaires at baseline and every 3 months x 1 year, followed by every 6 months x 2 years. Patient partners will also be allowed to enroll and will receive questionnaires on the same schedule (baseline, q3 months x 1 year, q6 months x 2 years).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult men (>18) diagnosed with ejaculatory and/or orgasmic dysfunction who were recommended to begin any treatment for the condition For partners, inclusion is being a sexual partner of a man with ejaculatory and/or orgasmic dysfunction who is receiving treatment
Key inclusion criteria (2 listed)
- Men being treated for either ejaculatory and/or orgasmic dysfunction
- For partners, inclusion is being a sexual partner of a man with ejaculatory and/or orgasmic dysfunction who is receiving treatment
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Primary Objective
Time frame: 3 years
Report subjective efficacy of therapies used to treat ejaculatory dysfunction. Study participants will have the option of indicating if they had used any treatments to treat ejaculatory disorders. If so, they will then be asked to measure its efficacy at improving their symptoms using a 1-10 scale (10 being very effective).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: No. Deidentified data will be made available to sites which have referred patients to the registry.
Related trials for Ejaculatory Dysfunction
Not yet recruiting
Male Pelvic Floor Muscle Rehabilitation Exercises
Erectile Dysfunction, Urinary Incontinence
RecruitingPhase 2
Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)
Premature Ejaculation
Not yet recruitingPhase 2
Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE
Premature Ejaculation
Recruiting
Emsella Chair vs Sham for Male Sexual Dysfunction
Male Sexual Dysfunction, Ejaculatory Dysfunction
Recruiting
Water Vapor Thermal Therapy Versus Ejaculation-Sparing Bipolar Transurethral Enucleation for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ejaculatory Dysfunction and Premature Ejaculation, run by Charitable Union for the Research and Education of Peyronie's Disease at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Objective (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.